Short answer
No, not every keratoconus patient is a transplant candidate. With cross-linking applied in the early stages, a corneal transplant can often be delayed or avoided. However, this method is protective rather than corrective: using riboflavin and UV-A, it creates new bonds in corneal collagen to stop disease progression. It may not be suitable with severe thinning, scar tissue or very advanced keratoconus; other approaches are needed in those cases.
Keratoconus is an eye disease characterized by thinning and bulging of the cornea, which usually begins at a young age and progresses over time, seriously impairing visual quality.
In this disease, the cornea, the transparent front layer of the eye, loses its normal dome shape and takes on a cone shape bulging outward. This change prevents light from focusing properly on the retina and leads to blurred or distorted vision.
Is keratoconus always treated with a transplant?
No. Not every keratoconus patient is a transplant candidate.
Today, thanks to the Cross-Linking (CXL) method applied in the early stages of the disease, a corneal transplant can often be delayed or even avoided altogether.
But an important reminder is necessary at this point:
➡️ Cross-Linking is a protective, not a corrective, treatment.
In other words, it aims to stop the progression of the disease rather than to correct the existing visual impairment.
What Is Cross-Linking and How Is It Performed?
Cross-Linking (CXL) is a treatment protocol developed to increase the mechanical strength of the cornea and prevent progressive keratoconus.
The application process consists of highly controlled and scientifically well-established steps:
Treatment steps:
-
Riboflavin (vitamin B2) is dropped onto the eye.
Before and during treatment, riboflavin is dropped onto the cornea at set intervals. This vitamin is a photosensitizing substance that can be activated by light. -
UV-A light is applied.
Riboflavin is activated with a low dose of ultraviolet-A (UV-A) light. This activation triggers the formation of new chemical bonds between the collagen fibers in the cornea. -
New cross-links form.
As a result of this process, the corneal tissue is, so to speak, "tightened." The new cross-links formed markedly increase the mechanical resistance of the cornea and prevent progressive structural deterioration.
So, who is suitable for Cross-Linking?
This treatment is most often preferred for patients in the following groups:
-
Those in the early or moderate stage of keratoconus
-
Those whose vision has not yet been seriously impaired
-
Those whose corneal thickness remains within the limit
-
Cases in which the disease shows signs of progression
In the presence of severe corneal thinning, development of scar tissue, or very advanced-stage keratoconus, treatment may require different approaches.
What should be expected after treatment?
Although the recovery process after Cross-Linking varies from person to person, relief generally begins within a few days.
Some patients may experience temporary blurred vision, a stinging sensation or light sensitivity.
But most importantly:
After treatment, the progression of the disease is largely halted, and for many patients this means vision loss is prevented.
"Keratoconus is a progressive disease. However, if intervention is made at the right time, it may be possible to preserve clear vision for life. Cross-Linking treatment is an important step that can change the course of keratoconus. Early diagnosis is the key to everything here."
Protecting Your Eyes Early Brightens Your Future
Although keratoconus is a disease that threatens vision over time, it can now be brought under control thanks to modern treatment approaches.
Cross-Linking stands out as an effective treatment option that strengthens the cornea and slows the progression of the disease.
Do not neglect your routine eye examinations.
Early diagnosis is always the most effective treatment.
Scientific references
- Hafezi F, Kling S, Hafezi NL, et al.. Corneal cross-linking. Prog Retin Eye Res. 2025. PMID: 39681212
- Santodomingo-Rubido J, Carracedo G, Suzaki A, et al.. Keratoconus: An updated review. Cont Lens Anterior Eye. 2022. PMID: 34991971
- Gomes JA, Tan D, Rapuano CJ, et al.. Global consensus on keratoconus and ectatic diseases. Cornea. 2015. PMID: 25738235



